Abstract 4441
Background
Cryo is an effective intervention for palliation and local control for small primary and metastatic tumours in mRCC. Pre-clinical murine tumour modeling found cryo recruits effector immune cells and synergizes with anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) to inhibit tumour rechallenge as compared to either therapy (tx) alone, leading to a prospective pilot study evaluating safety/tolerability.
Methods
NCT02626130 randomized pts to treme (CTLA-4) 10mg/kg every 4 weeks alone (arm A) or after cryo (arm B) for two doses followed by surgery (sx) or biopsy (bx) followed by maintenance treme. Best confirmed responses (ORR) were defined using RECIST v1.1, toxicity (tox) tabulated using CTCAE v4 with ≥ grade 3 adverse events (AE) possibly related reported, and time on study was defined as event free survival (EFS). Immune monitoring data (IMD): tissue based IHC, CyTOF, and RNA Nanostring.
Results
30 pts accrued, 29 pts received tx on study. More patients in Arm B had intermediate and poor risk disease as per IMDC criteria and had received >1 line of treatment as compared to Arm A leading to an imbalance between arms. Toxicity on study was similar between arms with six patients on each arm requiring treatment discontinuation due to AEs. IMD found clear cell histology (CC) had an inflamed tumor microenvironment (TME) with increased immune infiltration (IC) post treme in both arms compared to non-clear cell (NCC). CyTOF analysis identified an activated CD4+ T cell cluster expressing ICOS in the TME of CC pts compared to NCC.
Conclusions
Cryo+treme was tolerated similar to treme alone. IMD found a differential TME response to treme in CC vs NCC pts and in EFS >3 mo vs EFS <3 mo. Longer follow up is needed to determine impact of cryo in clinical efficacy endpoints.Table:
963P
Arm A n = 14 | Arm B n = 15 | |
---|---|---|
Histology Clear cell (CC) Non-clear cell (NCC) | 9 5 | 9 6 |
IMDC Good (CC/NCC) Intermediate Poor | 4 (4/0) 9 (5/4) 1 (0/1) | 0 11 (6/5) 4 (3/1) |
Prior nephrectomy | 7 (50%) | 5 (33%) |
Prior treatment 0 1 >1 | 10 2 2 | 10 0 5 |
Tissue collected | 6 sx, 4 bx, 4 no tissue | 5 sx, 4 bx, 6 NT |
ORR All (CC/NCC) PR SD PD Not measurable | 0 9 (7/2) 3 (2/1) 2 (0/2) | 1 (1/0) 4 (3/1) 5 (1/4) 5 (4/1) |
EFS mo (Arm A v Arm B) | 4.9 vs 3.2 (HR 0.73, 95%CI 0.35-1.58) | |
EFS mo (CC v NCC) | 3.3 vs 2.9 (HR 1.16, HR 95%CI 0.54-2.51) | |
EFS > 6 mo, #pts, (range) | Arm A: 4 (7.6-29.9), Arm B: 3 (6.3-30.3) | |
EFS> 6 mo (range) CC v NCC | CC: 4 (11.7-30.3), NCC 3 (6.3-7.8) |
Clinical trial identification
NCT02626130.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AztraZeneca.
Disclosure
M.T. Campbell: Honoraria (self): Pfizer; Honoraria (self): Genentech; Honoraria (self): Apricity Health LLC; Advisory / Consultancy: EMD Serono, Inc; Advisory / Consultancy: Genentech, Inc. E. Jonasch: Research grant / Funding (self), Research grant / Funding (institution): Exelixis; Research grant / Funding (self), Research grant / Funding (institution): Novartis; Research grant / Funding (self), Research grant / Funding (institution): Peloton; Research grant / Funding (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Eisai; Honoraria (self): Exelixis; Honoraria (self): Genentech; Honoraria (self): Ipsen; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Roche. A.Y. Shah: Honoraria (self): Eisai; Honoraria (self): Oncology Information Group; Honoraria (self): Roche Pharmaceuticals; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): BMS; Research grant / Funding (institution): EMD Serono. All other authors have declared no conflicts of interest.
Resources from the same session
1500 - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Presenter: Harriet Mintz
Session: Poster Display session 3
Resources:
Abstract
3524 - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).
Presenter: Paolo Tralongo
Session: Poster Display session 3
Resources:
Abstract
5637 - External Validation of a Prognostic Score in First-Line Metastastic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: David Lorente
Session: Poster Display session 3
Resources:
Abstract
3228 - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry
Presenter: Jessica Notohardjo
Session: Poster Display session 3
Resources:
Abstract
4695 - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database
Presenter: Junru Chen
Session: Poster Display session 3
Resources:
Abstract
4438 - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT
Presenter: Morgane Guibert-broudic
Session: Poster Display session 3
Resources:
Abstract
4574 - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT)
Presenter: Amelia Altavilla
Session: Poster Display session 3
Resources:
Abstract
3816 - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): results from the Dutch CAPRI registry
Presenter: Malou Kuppen
Session: Poster Display session 3
Resources:
Abstract
5180 - A phase 2a study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
1067 - Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Presenter: Carole Mercier
Session: Poster Display session 3
Resources:
Abstract